Childhood trauma and treatment outcomes during mood-stabilising treatment with lithium or quetiapine among outpatients with bipolar disorder.

"CONFLICT OF INTEREST ALW has received grant/research support from Deakin University. OKF has received speaker fees from Lundbeck. LS has received personal fees from United Biosource Corporation, Clintara, Bracket, and Clinical Trials Network and Institute; royalty fees from New Harbinger; grants from National Institute of Mental Health, Patient‐Centered Outcomes Research Institute, American Foundation for Suicide Prevention, and Takeda. SER has received grant/research support from Deakin University. OMD has received grant/research support from the Brain and Behavior Foundation, Simons Autism Foundation, Stanley Medical Research Institute, Deakin University, Lilly, NHMRC and Australasian Society for Bipolar and Depressive Disorders (ASBDD)/Servier. OMD has also received in kind support from BioMedica Nutraceuticals, NutritionCare and Bioceuticals. MT is a former full‐time employee at Lilly (1997–2008); he has been a consultant for AstraZeneca, Abbott, BMS, Lilly, GSK, J&J, Otsuka, Roche, Lundbeck, Elan, Alkermes, Allergan, AbbVie, Intracellular Therapies, Merck, Minerva, Neurocrine, Pamlab, Alexza, Forest, Teva, Sunovion and Gedeon Richter; his spouse is a former employee at Lilly (1998–2013). MM has consulted for Janssen and Otsuka Pharmaceuticals and has received research funding from Janssen Pharmaceuticals. TAK has received grant/research support from AstraZeneca Pharmaceuticals LP, Cephalon Inc., Eli Lilly and Company, Pfizer Inc., Dainippon Sumitomo Pharmaceuticals/Sepracor, Inc. Sepracor, Inc; he has also consulted for Bristol Myers Squibb Company, Cephalon Inc., Dainippon Sumitomo Pharmaceuticals/Sepracor, Inc., Merck & Co., Inc. and has received honoraria or royalties from AstraZeneca Pharmaceuticals LP, GlaxoSmithKline, American Psychiatric Publishing, Inc; his spouse is an employee at Johnson & Johnson. RCS has received grant/research support from Acadia Pharmaceuticals, Alkermes, Inc., Allergan, Plc, Assurex, Inc., Avanir Pharmaceuticals, Inc., Cerecor, Inc., Intracellular Therapies, Janssen Pharmaceutica, LivaNova PLC, Navitor Pharmaceuticals, Neurorx, Novartis Pharmaceuticals, Otsuka America, Takeda Pharmaceuticals. RCS has also consulted for Acadia Pharmaceuticals, Allergan plc, Alfasigma USA Inc., Myriad Neuroscience, Novartis International AG, Evecxia Therapeutics, Sunovion Pharmaceuticals Inc., Neurorx, Inc., Seelos Therapeutics. MJO is a full‐time employee of the United States Department of Veterans Affairs and has received research support from Otsuka. MJO has also consulted for Janssen and Neurocrine. In the last five years, DVI has received consulting honoraria from Alkermes, Allergan, Axsome, Biogen, Centers for Psychiatric Excellence, Jazz, Lundbeck, Otsuka, Precision Neuroscience, Sage, Sunovion; he has received research support (through his academic institutions) from Alkermes, Astra Zeneca, Brainsway, Litecure, Neosync, Otsuka, Roche, Shire. MB has received grant/research support from the NIH, Cooperative Research Centre, Simons Autism Foundation, Cancer Council of Victoria, Stanley Medical Research Foundation, Medical Benefits Fund, National Health and Medical Research Council, Medical Research Futures Fund, Beyond Blue, Rotary Health, A2 milk company, Meat and Livestock Board, Woolworths, Avant and the Harry Windsor Foundation, has been a speaker for Astra Zeneca, Lundbeck, Merck, Pfizer, and served as a consultant to Allergan, Astra Zeneca, Bioadvantex, Bionomics, Collaborative Medicinal Development, Lundbeck Merck, Pfizer and Servier. AT has received travel/grant support from NHMRC, AMP Foundation, Stroke Foundation, Hunter Medical Research Institute, Helen Macpherson Smith Trust, Schizophrenia Fellowship NSW, SMHR, ISAD, the University of Newcastle and Deakin University. AAN is a consultant for the Abbott Laboratories, Alkermes, American Psychiatric Association, Appliance Computing Inc. (Mindsite), Basliea, Brain Cells, Inc., Brandeis University, Bristol Myers Squibb, Clintara, Corcept, Dey Pharmaceuticals, Dainippon Sumitomo (now Sunovion), Eli Lilly and Company, EpiQ, L.P./Mylan Inc., Forest, Genaissance, Genentech, GlaxoSmithKline, Hoffman LaRoche, Infomedic, Intra‐Cellular Therapies, Lundbeck, Janssen Pharmaceutica, Jazz Pharmaceuticals, Medavante, Merck, Methylation Sciences, Naurex, NeuroRx, Novartis, Otsuka, PamLabs, Parexel, Pfizer, PGx Health, Ridge Diagnostics Shire, Schering‐Plough, Somerset, Sunovion, Takeda Pharmaceuticals, Targacept and Teva; consulted through the MGH Clinical Trials Network and Institute (CTNI) for Astra Zeneca, Brain Cells, Inc, Dianippon Sumitomo/Sepracor, Johnson and Johnson, Labopharm, Merck, Methylation Science, Novartis, PGx Health, Shire, Schering‐Plough, Targacept and Takeda/Lundbeck Pharmaceuticals. He receives grant/research support from American Foundation for Suicide Prevention, AHRQ, Brain and Behavior Research Foundation, Bristol Myers Squibb, Cederroth, Cephalon, Cyberonics, Elan, Eli Lilly, Forest, GlaxoSmithKline, Janssen Pharmaceutica, Intra‐Cellular Therapies, Lichtwer Pharma, Marriott Foundation, Mylan, NIMH, PamLabs, PCORI, Pfizer Pharmaceuticals, Shire, Stanley Foundation, Takeda and Wyeth‐Ayerst. Honoraria include Belvoir Publishing, University of Texas Southwestern Dallas, Brandeis University, Bristol Myers Squibb, Hillside Hospital, American Drug Utilization Review, American Society for Clinical Psychopharmacology, Baystate Medical Center, Columbia University, CRICO, Dartmouth Medical School, Health New England, Harold Grinspoon Charitable Foundation, IMEDEX, Israel Society for Biological Psychiatry, Johns Hopkins University, MJ Consulting, New York State, Medscape, MBL Publishing, MGH Psychiatry Academy, National Association of Continuing Education, Physicians Postgraduate Press, SUNY Buffalo, University of Wisconsin, University of Pisa, University of Michigan, University of Miami, University of Wisconsin at Madison, World Congress of Brain Behavior and Emotion, APSARD, ISBD, SciMed, Slack Publishing and Wolters Kluwer Publishing ASCP, NCDEU, Rush Medical College, Yale University School of Medicine, NNDC, Nova Southeastern University, NAMI, Institute of Medicine, CME Institute, ISCTM. He was currently or formerly on the advisory boards of Appliance Computing, Inc., Brain Cells, Inc., Eli Lilly and Company, Genentech, Johnson and Johnson, Takeda/Lundbeck, Targacept, and InfoMedic. He owns stock options in Appliance Computing, Inc., Brain Cells, Inc, and MedAvante; has copyrights to the Clinical Positive Affect Scale and the MGH Structured Clinical Interview for the Montgomery Asberg Depression Scale exclusively licensed to the MGH Clinical Trials Network and Institute (CTNI)."

"Funding information"